Aurobindo Faulted In US FDA Warning Letter For Poor Root Cause Investigations

Root cause investigations into impurities and equipment maintenance that fell short led the US Food and Drug Administration to issue Aurobindo Pharma Ltd. a warning letter on 20 June.

Aurobindo’s impurities investigation focused on impurities in an undisclosed active pharmaceutical ingredient that the European Directorate for the